Joseph Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joseph Taylor has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- John G. Gribben
Queen Mary University of London
3 shared publications - Daniel Kreuter
Precision Health University Research Institute, Queen Mary University of London, London, UK
2 shared publications Maria Calaminici
Department of Cellular Pathology Royal London Hospital Barts Health NHS Trust London UK
2 shared publicationsSuthesh Sivapalaratnam
Precision Health University Research Institute, Queen Mary University of London, London, UK; Department of Clinical Haematology, Royal London Hospital, Barts Health NHS Trust, London, UK; Blizard Institute, Queen Mary University of London, London, UK
2 shared publicationsAndrew Clear
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London
1 shared publication- Andrew Clear
Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom
1 shared publication
Latest Publications
- 27 June 2026
- Published by Elsevier in European Journal of Internal Medicine
- p. 107029
Understanding the Barriers to Translating Artificial Intelligence into the Clinical Laboratory
- 27 June 2026
- Published by Elsevier in European Journal of Internal Medicine
- p. 107029
Understanding the Barriers to Translating Artificial Intelligence into the Clinical Laboratory
- Open Access
TRBC1/TRBC2 Immunophenotyping Provides Added Value During the Diagnostic Workup of T‐Cell Lymphoma
Background: Molecular T‐cell receptor (TCR) clonality testing cannot link clonality to immunophenotype, limiting discrimination between malignant and clonal reactive T‐cell expansions. Methods: We evaluated TRBC1/TRBC2 immunophenotyping in 50 consecutive cases with suspected T‐cell malignancy, assessing restriction (ratio > 10) across T‐cell subsets. Results: TRBC immunophenotyping showed 100% sensitivity for T‐cell malignancy if assessed within subsets or phenotypically abnormal populations. Malignant clones predominantly showed CD4αβ/CD8αβ restriction (18/21), while reactive clones predominantly showed γδ/dual‐positive/dual‐negative restriction (15/16), enabling enhanced discrimination. Conclusion: TRBC immunophenotyping provides sensitive clonality detection with phenotypic lineage assignment, adding diagnostic clarity beyond molecular testing and supporting integration into routine workflows. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission.
Open AccessTRBC1/TRBC2 Immunophenotyping Provides Added Value During the Diagnostic Workup of T‐Cell Lymphoma
Background: Molecular T‐cell receptor (TCR) clonality testing cannot link clonality to immunophenotype, limiting discrimination between malignant and clonal reactive T‐cell expansions. Methods: We evaluated TRBC1/TRBC2 immunophenotyping in 50 consecutive cases with suspected T‐cell malignancy, assessing restriction (ratio > 10) across T‐cell subsets. Results: TRBC immunophenotyping showed 100% sensitivity for T‐cell malignancy if assessed within subsets or phenotypically abnormal populations. Malignant clones predominantly showed CD4αβ/CD8αβ restriction (18/21), while reactive clones predominantly showed γδ/dual‐positive/dual‐negative restriction (15/16), enabling enhanced discrimination. Conclusion: TRBC immunophenotyping provides sensitive clonality detection with phenotypic lineage assignment, adding diagnostic clarity beyond molecular testing and supporting integration into routine workflows. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission.
- Open Access
Artificial Intelligence for Pre-Anaemic Iron Deficiency Detection Using Rich Complete Blood Count Data
Iron deficiency (ID) is a major contributor to global disease burden and the leading cause of anaemia. Early detection is important for proactive management, but conventional complete blood count (CBC) screening often fails to identify non-anaemic iron deficiency (NAID) as many individuals maintain haemoglobin and red cell indices within reference ranges. Analysing 153,565 subjects from the INTERVAL, COMPARE and STRIDES studies, we show that CBC screening has only 40.5 % sensitivity for ID detection, falling to 21.9 % for NAID, highlighting a detection gap. CBC analysers generate a wealth of data beyond Electronic Health Record CBC parameters. We demonstrate that artificial intelligence applied to single-cell flow cytometry data from the CBC analyser achieves 83.7 % sensitivity for ID and 79.3 % for NAID. Our findings show that AI can greatly improve detection of a high-prevalence, important condition without changing infrastructure or diagnostic pathways, providing a valuable tool for proactive anaemia management.
Open AccessArtificial Intelligence for Pre-Anaemic Iron Deficiency Detection Using Rich Complete Blood Count Data
Iron deficiency (ID) is a major contributor to global disease burden and the leading cause of anaemia. Early detection is important for proactive management, but conventional complete blood count (CBC) screening often fails to identify non-anaemic iron deficiency (NAID) as many individuals maintain haemoglobin and red cell indices within reference ranges. Analysing 153,565 subjects from the INTERVAL, COMPARE and STRIDES studies, we show that CBC screening has only 40.5 % sensitivity for ID detection, falling to 21.9 % for NAID, highlighting a detection gap. CBC analysers generate a wealth of data beyond Electronic Health Record CBC parameters. We demonstrate that artificial intelligence applied to single-cell flow cytometry data from the CBC analyser achieves 83.7 % sensitivity for ID and 79.3 % for NAID. Our findings show that AI can greatly improve detection of a high-prevalence, important condition without changing infrastructure or diagnostic pathways, providing a valuable tool for proactive anaemia management.
- Open Access
- 15 February 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16 (1) , 372
An anorexia nervosa network derived from human brain lesions
- 15 February 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16 (1) , 372
Open AccessAn anorexia nervosa network derived from human brain lesions
- Open Access
- 15 November 2022
- Published by Taylor & Francis
- p. 47-59
A League is born: the League of Ireland's inaugural season, 1921–1922
- 15 November 2022
- Published by Taylor & Francis
- p. 47-59
Open AccessA League is born: the League of Ireland's inaugural season, 1921–1922
- Open Access
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 658
Beyond Exhaustion: The PDL1-PD1 Axis Shapes the Classical Hodgkin Lymphoma Microenvironment
Background: PD1 inhibitor (PD1i) efficacy is taken as evidence of T cell exhaustion in Classical Hodgkin Lymphoma (CHL), however, direct evidence for exhaustion is limited. PD1 expression does not predict PD1i response in CHL. Additionally, PDL1 and PD1 expression are not correlated and are independently prognostic. This suggests a more complex picture than PD1 expression simply reflecting exhaustion induced by PDL1. Aim: To investigate PD1/PDL1 interaction in CHL Methods: 149 CHL cases were compared to 27 reactive lymph node controls (RLN) by immunohistochemistry (IHC). PD1 expression was validated with two clones. Multiplex IHC (mIHC) was performed in 47 CHL and 27 RLN by stripping, reprobing and image alignment. Imaging Mass Cytometry (IMC) was analysed by t-SNE clustering and spatial point pattern modelling (SPPM). SPPM is a powerful technique adopted from other disciplines and its use in multiplex image analysis is novel. Flow-based CFSE proliferation and cytokine assays were performed in 15 CHL and 5 RLN single cell suspensions (SCS) with CD3/28 and PMA/Ionomycin stimulation. Co-cultures were with KMH2 and L428 cell lines and healthy donor naïve T helper cells (TH). Results: We evaluated PDL1 expression by IHC and found that PDL1hi CHL cells were surrounded by PDL1+ macrophages (Mφ), consistent with the literature. Mφ PDL1 intensity correlated inversely with distance from CHL cells consistent with induction by a CHL-secreted factor (p <0.001), a finding we validated in vitro (p <0.001). Deep phenotyping using IMC identified CD14+CD16-CD163-PDL1+-, CD14-CD68+CD163-PDL1+ and CD14+CD16+CD163+PDL1- myeloid subsets by t-SNE. SPPM revealed that tumor and vessel location predicted their distribution with subsets one and two localising to tumor whilst subset three localised to vessel. Our data supports the hypothesis that CHL recruits and induces a PDL1+ myeloid environment. We next sought evidence of T cell exhaustion. PD1 expression by IHC was lower in CHL than RLN (p<0.001). Cells co-expressing PD1 with TIM3 or LAG3 were significantly reduced in CHL compared to RLN by mIHC. Cells co-expressing PD1 with TBET or EOMES were reduced in or showed no significant difference between CHL and RLN. No correlation was seen between PD1 and PDL1 expression. We performed functional validation, evaluating proliferative and IL2/IFNγ production capacity, and identified no significant difference between CHL and RLN SCS with or without the addition of Pembrolizumab or isotype control. This constitutes a more detailed assessment of exhaustion with higher case numbers than publications to date. Our data does not support the presence of an exhausted T population above that seen in reactive controls and finds no relationship between PD1 and PDL1 expression. The absence of exhaustion does not exclude a role for the PD1-PDL1 axis, which regulates multiple facets of T cell homeostasis including motility, differentiation (skewing towards T regulatory cells (TReg)), and TReg effector functions. Many of these are characterised by transient PD1 expression unlike the sustained expression seen in exhaustion. In contrast to PD1, CHL PDL1 and MHC class 2 expression do predict PD1i response. CHL MHC2 expression suggests antigen presentation and a role for TH cells. This led us to examine connections between PDL1 and the TH compartment. Co-culture of CHL cell lines with naïve TH led to enrichment of CD25hiCD127loFOXP3+ TReg which upregulated PD1 compared to TReg from paired CD3/28 controls (p<0.001). FOXP3+ cells were enriched by IHC compared to RLN (p<0.001). Unlike PD1, FOXP3 associated with CHL MHC2 expression (p=0.012), which in turn associated with PDL1 expression (p=0.02). SPPM of TC and TH subsets revealed that PDL1 expression predicted the location of FOXP3+ TReg and negatively predicted the location of TC and TH17. PDL1 was a stronger predictor than CHL cell density. These data support a role for PDL1 in shaping T differentiation and trafficking irrespective of observed PD1 expression. Conclusion: We find that CHL cells are PDL1hi and induce a PDL1+ myeloid environment, but detect little evidence of T exhaustion. Instead we find that PDL1 expression shapes T (particularly TReg) differentiation and trafficking. Our data challenges the narrative that PD1i in CHL act by reversing exhaustion and highlights novel mechanisms with the potential to provide insight into CHL biology and inform the hunt for biomarkers of response. Figure Disclosures Gribben: Acerta/Astra Zeneca: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding.
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 658
Open AccessBeyond Exhaustion: The PDL1-PD1 Axis Shapes the Classical Hodgkin Lymphoma Microenvironment
Background: PD1 inhibitor (PD1i) efficacy is taken as evidence of T cell exhaustion in Classical Hodgkin Lymphoma (CHL), however, direct evidence for exhaustion is limited. PD1 expression does not predict PD1i response in CHL. Additionally, PDL1 and PD1 expression are not correlated and are independently prognostic. This suggests a more complex picture than PD1 expression simply reflecting exhaustion induced by PDL1. Aim: To investigate PD1/PDL1 interaction in CHL Methods: 149 CHL cases were compared to 27 reactive lymph node controls (RLN) by immunohistochemistry (IHC). PD1 expression was validated with two clones. Multiplex IHC (mIHC) was performed in 47 CHL and 27 RLN by stripping, reprobing and image alignment. Imaging Mass Cytometry (IMC) was analysed by t-SNE clustering and spatial point pattern modelling (SPPM). SPPM is a powerful technique adopted from other disciplines and its use in multiplex image analysis is novel. Flow-based CFSE proliferation and cytokine assays were performed in 15 CHL and 5 RLN single cell suspensions (SCS) with CD3/28 and PMA/Ionomycin stimulation. Co-cultures were with KMH2 and L428 cell lines and healthy donor naïve T helper cells (TH). Results: We evaluated PDL1 expression by IHC and found that PDL1hi CHL cells were surrounded by PDL1+ macrophages (Mφ), consistent with the literature. Mφ PDL1 intensity correlated inversely with distance from CHL cells consistent with induction by a CHL-secreted factor (p <0.001), a finding we validated in vitro (p <0.001). Deep phenotyping using IMC identified CD14+CD16-CD163-PDL1+-, CD14-CD68+CD163-PDL1+ and CD14+CD16+CD163+PDL1- myeloid subsets by t-SNE. SPPM revealed that tumor and vessel location predicted their distribution with subsets one and two localising to tumor whilst subset three localised to vessel. Our data supports the hypothesis that CHL recruits and induces a PDL1+ myeloid environment. We next sought evidence of T cell exhaustion. PD1 expression by IHC was lower in CHL than RLN (p<0.001). Cells co-expressing PD1 with TIM3 or LAG3 were significantly reduced in CHL compared to RLN by mIHC. Cells co-expressing PD1 with TBET or EOMES were reduced in or showed no significant difference between CHL and RLN. No correlation was seen between PD1 and PDL1 expression. We performed functional validation, evaluating proliferative and IL2/IFNγ production capacity, and identified no significant difference between CHL and RLN SCS with or without the addition of Pembrolizumab or isotype control. This constitutes a more detailed assessment of exhaustion with higher case numbers than publications to date. Our data does not support the presence of an exhausted T population above that seen in reactive controls and finds no relationship between PD1 and PDL1 expression. The absence of exhaustion does not exclude a role for the PD1-PDL1 axis, which regulates multiple facets of T cell homeostasis including motility, differentiation (skewing towards T regulatory cells (TReg)), and TReg effector functions. Many of these are characterised by transient PD1 expression unlike the sustained expression seen in exhaustion. In contrast to PD1, CHL PDL1 and MHC class 2 expression do predict PD1i response. CHL MHC2 expression suggests antigen presentation and a role for TH cells. This led us to examine connections between PDL1 and the TH compartment. Co-culture of CHL cell lines with naïve TH led to enrichment of CD25hiCD127loFOXP3+ TReg which upregulated PD1 compared to TReg from paired CD3/28 controls (p<0.001). FOXP3+ cells were enriched by IHC compared to RLN (p<0.001). Unlike PD1, FOXP3 associated with CHL MHC2 expression (p=0.012), which in turn associated with PDL1 expression (p=0.02). SPPM of TC and TH subsets revealed that PDL1 expression predicted the location of FOXP3+ TReg and negatively predicted the location of TC and TH17. PDL1 was a stronger predictor than CHL cell density. These data support a role for PDL1 in shaping T differentiation and trafficking irrespective of observed PD1 expression. Conclusion: We find that CHL cells are PDL1hi and induce a PDL1+ myeloid environment, but detect little evidence of T exhaustion. Instead we find that PDL1 expression shapes T (particularly TReg) differentiation and trafficking. Our data challenges the narrative that PD1i in CHL act by reversing exhaustion and highlights novel mechanisms with the potential to provide insight into CHL biology and inform the hunt for biomarkers of response. Figure Disclosures Gribben: Acerta/Astra Zeneca: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding.
- 31 December 2018
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (1) , e42-e44
Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy
We read with interest the recent paper published in Haematologica by Sasse et al . examining programmed cell death protein – 1 (PD1) expression in paired pretreatment/relapse samples for patients receiving PD1 inhibitor therapy in classical Hodgkin lymphoma (CHL).[1][1] Although the authors
- 31 December 2018
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (1) , e42-e44
Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy
We read with interest the recent paper published in Haematologica by Sasse et al . examining programmed cell death protein – 1 (PD1) expression in paired pretreatment/relapse samples for patients receiving PD1 inhibitor therapy in classical Hodgkin lymphoma (CHL).[1][1] Although the authors
- 1 October 2015
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 34, 36-45
Microenvironment abnormalities and lymphomagenesis: Immunological aspects
- 1 October 2015
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 34, 36-45
Microenvironment abnormalities and lymphomagenesis: Immunological aspects
- 18 May 2015
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 9 (5) , 473-482
The Role of the Tumor Microenvironment in HIV-Associated Lymphomas
There has been considerable interest in the role of the lymphoma microenvironment. Despite the use of highly active antiretroviral therapy (HAART), AIDS-related diffuse large-B-cell lymphoma remain...
- 18 May 2015
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 9 (5) , 473-482
The Role of the Tumor Microenvironment in HIV-Associated Lymphomas
There has been considerable interest in the role of the lymphoma microenvironment. Despite the use of highly active antiretroviral therapy (HAART), AIDS-related diffuse large-B-cell lymphoma remain...
- 1 March 2007
- Published by SAGE Publications in Clinical Ethics
- Vol. 2 (1) , 50-54
NICE, Alzheimer's and the QALY
The introduction of National Institute for Health and Clinical Excellence (NICE) guidance on Alzheimer's medication in November 2006 will have a significant effect on the treatment of patients, and is opposed by the Royal College of Psychiatrists and many charities dealing with the elderly. The use of the Quality-Adjusted Life Year (QALY) in the guidance formulation is much debated due to questions of ageism. This article seeks to examine the basis of these accusations and whether NICE can be justified using a utilitarian calculation in a principally egalitarian system such as the NHS.
- 1 March 2007
- Published by SAGE Publications in Clinical Ethics
- Vol. 2 (1) , 50-54
NICE, Alzheimer's and the QALY
The introduction of National Institute for Health and Clinical Excellence (NICE) guidance on Alzheimer's medication in November 2006 will have a significant effect on the treatment of patients, and is opposed by the Royal College of Psychiatrists and many charities dealing with the elderly. The use of the Quality-Adjusted Life Year (QALY) in the guidance formulation is much debated due to questions of ageism. This article seeks to examine the basis of these accusations and whether NICE can be justified using a utilitarian calculation in a principally egalitarian system such as the NHS.